Kyphoplasty Medicare Fraud: How Manufacturer Advice Became a Hospital Campaign

Kyphoplasty Medicare fraud cases alleged that device sales advice led hospitals to bill Medicare for unnecessary inpatient admissions. The government alleged that Kyphon encouraged those admissions, causing hospitals to submit higher Medicare claims. The advice started with a device manufacturer. The claims came from hospitals across the country. If you worked in device sales, reimbursement, utilization review or hospital billing, the connection may sound familiar: a vendor’s explanation of how a procedure pays becomes an instruction about how a patient should be admitted.

Why Inpatient Status Mattered

Kyphoplasty treats certain spinal fractures, often associated with osteoporosis. Balloon kyphoplasty uses a balloon to create a cavity in the fractured vertebra, then fills that space with bone cement. Kyphon sold the instruments used in the procedure. The hospital bought the equipment, a physician performed the treatment, and Medicare paid for the care.

Hospital reimbursement made the admission decision commercially important. Inpatient payment generally absorbs device costs into a payment based on the patient’s diagnosis and procedures. Hospital outpatient payment also generally packages the device into payment for the service, while physicians bill separately.

The amended complaint put Kyphon’s kit price at approximately $3400, against approximately $2000 in hospital outpatient reimbursement beginning in January 2005. The original complaint described inpatient payments as of October 2003 of approximately $6,000 to approaching $10,000, depending on the billing group and geography. In the alleged sales strategy, getting the patient admitted unlocked the higher payment, and the hospital’s expected return helped sell the equipment.

The kyphoplasty allegations followed that difference. The government said hospitals admitted patients for procedures that could often have been performed safely in a less costly outpatient setting. The higher inpatient reimbursement made the manufacturer’s products more attractive to the hospital buying them.

The whistleblowers’ original complaint described the commercial obstacle plainly. Hospitals questioned whether they could afford to offer the procedure at outpatient reimbursement rates. The complaint alleged that Kyphon refused to lower its product price and instead pushed admission and billing practices that increased hospital revenue.

That is the troubling proposition we see in the allegations: make the hospital stay fit the price of the equipment. Medicare would pick up the difference.

How Kyphon’s Advice Reached the Hospital Claim

The complaints alleged a coordinated sales effort reaching hospital decision-makers, physicians and coders. They describe the practical steps between selling a device and causing a hospital to request a higher payment.

A Profit Model Built Around Admission

According to the original complaint, Kyphon developed an Economic Support Model after hospitals complained that they were losing money on kyphoplasty. It showed the reimbursement a hospital would receive under the inpatient payment system. The whistleblowers described how that tool reached the sales force:

The complaint said the sales force was eventually told to return its copies. The amended complaint described a model that assumed inpatient treatment and omitted an outpatient reimbursement comparison. That assumption matters. It puts the admission decision inside the financial pitch before a particular patient’s need for a hospital stay has entered the discussion.

From Sales Training to the Admission Order

The amended complaint alleged that representatives attended kyphoplasty procedures and were taught to ask operating-room nurses whether the patient had been admitted. If not, representatives would arrange for the physician to sign inpatient admission orders in the operating room. The complaint also alleged that representatives sometimes told physicians Medicare would not reimburse the hospital for outpatient treatment.

The original complaint separately described representatives and reimbursement managers visiting hospital coders. They allegedly advised coders how to reach higher-paying diagnosis-related groups and told physicians to document additional medical conditions that increased reimbursement.

These allegations connect identifiable work inside different organizations: the manufacturer’s training, the physician’s admission order and the hospital’s coding. Someone who attended the training may know why the instruction was given. Someone in the hospital may know how it became the claim.

Bone Biopsies and Physician Billing

The original complaint alleged that Kyphon encouraged physicians to biopsy every patient, including patients with no indication that a biopsy was needed. It described sales instructions to get the biopsy device onto surgeons’ preference cards and make sure coders recorded the biopsy so the hospital reached a higher-paying group.

The whistleblowers put the sales incentive in concrete terms: a biopsy tool costing $110 allegedly increased reimbursement by approximately $500 at the time. In their account, the additional procedure had become another selling point for the device. The complaint quoted a representative describing the effort to get hospital approval:

That is an alleged sales effort involving the operating room, the finance office and medical records together. The complaint said the biopsy device then allowed a different billing group and the hospitals wanted more cases.

It also described a change in the incentive. In early 2005, according to the pleading, Medicare reduced reimbursement for the biopsy group. A reimbursement director circulated an email about the lower payment weight. The reimbursement-manager whistleblower said the director intended to discourage promotion of biopsies for extra reimbursement and management chastised him for sending the message.

Physician reimbursement supplied a separate incentive. The complaint alleged that sales representatives encouraged billing kyphoplasty under open-reduction codes even though the procedure went through the skin rather than using an open operation. It also alleged that Kyphon’s reimbursement leadership objected to those codes and the sales force ignored the objections.

The complaint said unlisted CPT code 22899 triggered review, and representatives steered physicians toward alternative billing methods. It alleged that training presentations described open-treatment codes as potentially related to kyphoplasty and representatives directed physicians to other doctors to learn how they billed. Someone in sales could know who arranged that exchange and which reimbursement question prompted it.

Referrals and Free Supplies

The same complaint alleged that Kyphon’s Spine Education Specialist program used quotas and commissions tied to patient referrals. It alleged that company-paid representatives cultivated business for physicians performing kyphoplasty. The complaint also described promotional mailings and advertising provided for doctors.

Free supplies allegedly helped win hospital business. According to the complaint, representatives requested no-charge purchase orders so they could show hospitals how much they had saved through free product. Those orders connect a commercial concession to a particular hospital account.

One example in the original complaint concerned an HCA hospital in Nashville that was reluctant to offer kyphoplasty because outpatient reimbursement was poor. The hospital did not believe it could offer the procedure exclusively on an inpatient basis. A representative allegedly offered free supplies for outpatient procedures. For someone managing hospital accounts, the discussion about admissions and the negotiation over supplies could be parts of the same sale.

The admission allegations became the common thread in the manufacturer’s resolution and the successive hospital settlements. The complaints describe how the sales program allegedly worked. The settlements show where the government pursued the resulting inpatient claims.

The Manufacturer’s Settlement Came First

Medtronic Spine, Kyphon’s corporate successor, agreed to a $75 million civil settlement announced on May 22, 2008. The government alleged that the company encouraged unnecessary inpatient kyphoplasty admissions, causing providers to submit false Medicare claims. The agreement provided a collective whistleblower share of $14.9 million.

The qui tam case came from people who knew both sides of the sales pitch: a regional sales manager and a reimbursement manager. The original complaint described responsibilities spanning surgeon training, hospital accounts, coding questions and efforts to improve reimbursement. Their work put them where the equipment sale met the hospital’s payment concerns.

The later hospital campaign involved a separate action brought by the same whistleblowers.

Hospital Settlements Spread Across the Country

The hospital settlements concerned allegedly unnecessary inpatient admissions, with successive announcements covering different facilities. The Justice Department’s later account identified earlier hospital settlements in May and September 2009.

On May 17, 2010, nine hospitals in seven states agreed to pay more than $9.4 million. The announced collective whistleblower share was approximately $1.5 million.

The January 4, 2011 announcement covered seven hospitals in six states and more than $6.3 million. The collective whistleblower share was approximately $1.1 million.

A related hospital case shows why each settlement’s scope matters. Rex Healthcare agreed to a $1.9 million settlement announced on April 4, 2011. The government alleged unnecessary inpatient classification for kyphoplasty and other minimally invasive procedures. Its payment covered that broader set of allegations.

On February 7, 2012, fourteen hospitals agreed to pay more than $12 million. The collective whistleblower share was approximately $2.1 million.

The July 2, 2013 announcement covered 55 hospitals in 21 states. Its headline said more than $34 million. The collective whistleblower share announced for this wave was approximately $5.5 million.

On December 18, 2015, 32 hospitals in 15 states agreed to pay more than $28 million. The announced collective whistleblower share was approximately $4.75 million.

One Sales Strategy, a National Hospital Campaign

By the December announcement, the Justice Department reported settlements with more than 130 hospitals totaling approximately $105 million.

For an insider, the useful pattern is the repeated admission advice and the resulting claims. The national campaign shows how a manufacturer’s reimbursement strategy can reach many hospital accounts.

What Evidence Is Needed to Prove Fraud?

The useful evidence connects the manufacturer’s admission advice to the patient’s hospital record and the resulting Medicare claim. In the Kyphon complaints, that connection appears in sales training, the Economic Support Model, conversations with coders and arrangements for physicians to sign admission orders.

Sales presentations, admission orders and hospital claims can show how the advice became a bill. We help the people who handled those steps connect what they know to the alleged scheme.

A 2020 article in the Journal of Forensic and Investigative Accounting, A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, describes a recurring pattern in healthcare false-claims cases: requests for payment for more expensive categories of care than were provided. In kyphoplasty, the government’s allegation concerned whether patients needed the inpatient care billed around the procedure.

The complaints also show why the response to a billing objection can matter. The original pleading alleged that an HCA hospital stopped a physician from performing kyphoplasty there after the physician said admissions were intended to make money for the hospital. Elsewhere, it alleged that sales representatives ignored objections from reimbursement leadership. The contrast gives an insider a concrete question to discuss with us: who heard the objection, and what happened to the advice afterward?

A manufacturer employee may understand the origin of a financial model without handling the hospital’s claims. A hospital employee may see the orders and billing without knowing what the sales team was taught. We work with that business knowledge to connect the advice, the medical decision and the request for payment.

How Much Can a Medicare Fraud Whistleblower Receive?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Each accompanied a particular resolution, from the manufacturer agreement to the successive hospital settlements.

The sales and reimbursement roles here are especially instructive. The whistleblowers could explain why a manufacturer was involved in admission and coding decisions at all. For someone who has seen that same handoff, the conversation starts with what the advice was, who received it and how it reached billing.

When the Sales Advice Became the Admission Order

If you saw reimbursement advice steer kyphoplasty admissions or coding, speak to one of our whistleblower experts about what happened inside the account. We build your strongest kyphoplasty whistleblower case from the sales program and the hospital billing, find medical-device whistleblower lawyers who know hospital payment disputes, and stay beside you through the decisions ahead.